MVP Reports FY26 Results with Strong Performance
Key points
- Net profit after tax at $0.6 million, up from $0.1 million
- Group revenue up 9% to $42.6 million
- Penthrox volume growth of 28% in Australia, 18% in Europe
- Paediatric label for Penthrox approved and launched in UK and Europe
- Free cashflow improved by $5.8 million
Full summary
Medical Developments International Ltd (MVP) announced its full-year results for FY26, showing a net profit after tax of $0.6 million, up from $0.1 million in the prior corresponding period. Group revenue increased by 9% to $42.6 million. The Pain Management segment saw a 12% revenue growth, while the Respiratory segment experienced a 15% decline. Penthrox volume growth was 28% in the Australian hospital segment and 18% in Europe. The company launched Penthrox with a paediatric label in the UK and all European markets, broadening its market reach. Free cashflow improved by $5.8 million to $4.2 million.
Guidance
Net profit after tax $0.6 million for FY26, Group revenue $42.6 million, Penthrox volume growth 28% Australia, 18% Europe
Outlook
MVP expects higher Penthrox demand in FY27, stable Respiratory segment demand, and non-recurrence of FY26 inventory stocking benefits. Amortisation expense of ~$1 million related to European paediatric indication.
Summary generated by a large language model. Please interpret with care.